Our Mission

We are a molecular diagnostics company focusing on in vitro diagnostic tests for cancer. Our products are based on a unique and proprietary technology platform, which uses uses a fundamental biological phenomenon called DNA methylation as a source for highly informative and specific biomarkers, the core of every diagnostic test.

Despite coming from a history of pioneering in DNA methylation technology development and biomarker discovery, we quickly realized that interaction with patients and medical professionals is essential to develop innovative products that address urgent unmet challenges in cancer diagnosis and personalized medicine. Today we cover all steps necessary to provide commercially successful molecular diagnostic tests starting with asking the right clinical questions for accurate development and validation of biomarkers, to IVD test kit development and direct marketing and sales of our products to laboratories and physicians.

As much as we believe that we are the best advocates of our own products and have to spearhead driving their medical adoption, we also realize that the opportunity in cancer molecular diagnostics is too vast to leverage the potential of our products by ourselves. Therefore, we have adopted a dual business strategy: We we market our own products - known under the brand names Epi proColon and Epi proLung – in the home market of Germany, Austria, and Switzerland and through a steadily increasing network of distributors in the rest of Europe and the Middle East. At the same time, we have entered into non-exclusive partnerships through licensing our Septin9 biomarker for colorectal cancer and the assay technologies to detect it in blood plasma to some of the most distinguished companies in the clinical diagnostic space including Abbott, Qiagen, Sysmex, Quest Diagnostics, ARUP Laboratories, and Warnex Laboratories. We typically participate in the commercial success of our partners through upfront and milestone payments, but most importantly through royalties on the sales they generate with their diagnostic products and services based on our biomarker and technology.    

Besides cancer early detection and diagnosis, personalized medicine and companion diagnostics are widely recognized drivers of growth, both in the pharma and diagnostics market. Our experience in developing concept and biomarkers for drug response prediction goes back to the early days of personalized medicine, and we leverage this experience and know-how in multiple partnerships with pharma companies. In these partnerships, we discover and validate drug response biomarkers for our partners and develop high quality clinical assays with the potential to fuel our future product pipeline.